When the blood supply to bone is cut off, the tissue dies — and once bone collapses, it cannot rebuild itself without intervention. MSC therapy is being studied as a way to restore the vascular and cellular foundation that osteonecrotic bone has lost.

Avascular necrosis femoral head with MSC bone regeneration

Avascular necrosis (AVN), also called osteonecrosis, is a progressive condition in which bone tissue dies due to a disrupted blood supply. The femoral head — the ball of the hip joint — is the most commonly affected site, though AVN can also occur in the knee, shoulder, and ankle. An estimated 20,000 to 30,000 new cases are diagnosed in the United States each year, with the majority affecting adults between 30 and 50 years of age. [1]

Why AVN is so difficult to treat. Bone is a living tissue that remodels constantly — old bone is resorbed, new bone is laid down. When blood flow stops, the remodelling cycle breaks. Osteocytes die within 12–48 hours of ischemia, and the structural integrity of the bone begins to degrade. Without intervention, the affected bone segment collapses, leading to severe pain, joint deformity, and eventual osteoarthritis that typically requires total joint replacement. [2]

The core problem is vascular. The fundamental defect in AVN is not the bone itself but the blood vessels that feed it. Causes include corticosteroid use (responsible for ~35% of non-traumatic cases), excessive alcohol consumption, trauma such as fracture or dislocation, sickle cell disease, and coagulation disorders. In roughly 15–20% of cases, no cause is identified — these are classified as idiopathic. [3]

MSC therapy addresses both problems at once. Mesenchymal stem cells possess two properties directly relevant to AVN: they can differentiate into osteoblasts (bone-forming cells) and they secrete powerful angiogenic factors — VEGF, HGF, and angiopoietin-1 — that stimulate new blood vessel formation. Rather than simply replacing the dead bone with a metal prosthesis, MSC therapy aims to restore the biological environment that bone requires to survive. [4]

How Avascular Necrosis Progresses

AVN progresses through four recognised stages, from reversible marrow oedema to irreversible joint collapse. Understanding the stage is critical because the treatment window for biological interventions like MSC therapy narrows as the disease advances.

Stage I
Bone marrow oedema visible on MRI only. X-rays appear normal. The bone is ischemic but structurally intact. This is the ideal window for MSC therapy — the scaffold is still present.
Stage II
Sclerotic or cystic changes appear on X-ray. The femoral head retains its spherical shape. Core decompression with MSC grafting shows its strongest evidence at this stage.
Stage III
Subchondral fracture — the "crescent sign" — indicates structural failure of the bone beneath the cartilage. The joint surface may still be intact; MSC therapy may delay but not prevent collapse.
Stage IV
Femoral head collapse with secondary osteoarthritis. Joint space narrowing and acetabular involvement. Total hip replacement is usually indicated; MSCs may assist post-surgical recovery.

Early detection fundamentally changes the treatment landscape. A patient diagnosed at Stage I or II has a genuine opportunity to preserve their native hip joint. A patient diagnosed at Stage IV has already lost that option — but MSC therapy may still play a role in recovery after joint replacement surgery. [5]

How MSC Therapy Works for Avascular Necrosis

MSC therapy delivers mesenchymal stem cells — multipotent cells with immunomodulatory and regenerative properties — directly into the necrotic lesion. The goal is to replace the dead bone with living, vascularised tissue before structural collapse occurs.

Angiogenesis: Restoring the Blood Supply

New blood vessels are the prerequisite for new bone. MSCs secrete vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), and angiopoietin-1 — a cocktail of pro-angiogenic signals that stimulates endothelial cells to form new capillary networks. In preclinical models of femoral head necrosis, MSC-treated animals showed a 2- to 3-fold increase in vascular density within the necrotic zone compared to untreated controls. [6]

MSC bone regeneration and angiogenesis in osteonecrosis
MSCs promote both angiogenesis and osteogenesis in necrotic bone, addressing the dual deficit of blood supply and bone formation.

Osteogenesis: Building New Bone

MSCs are the body's natural osteoblast precursors. When delivered into a necrotic lesion, they respond to local calcium and phosphate gradients by upregulating Runx2 and osterix — the master transcription factors for osteoblast differentiation. Over a period of 8–16 weeks, these cells deposit osteoid matrix, which subsequently mineralises into mature lamellar bone. The new bone is biomechanically competent — it can bear weight. [7]

Immunomodulation: Stopping the Inflammatory Cascade

Necrotic bone triggers a sterile inflammatory response. Dying osteocytes release DAMPs (damage-associated molecular patterns) that activate local macrophages and osteoclasts, accelerating bone resorption. MSCs suppress this inflammatory loop by secreting TGF-β, IL-10, and PGE2 — shifting macrophages from a pro-inflammatory M1 phenotype to a tissue-repair M2 phenotype. The result is less osteoclast activity and a more favourable environment for bone formation. [8]

Key Mechanism Summary
MSCs address AVN through three concurrent mechanisms: (1) angiogenic factor secretion to restore blood supply, (2) direct differentiation into osteoblasts to lay down new bone matrix, and (3) paracrine immunomodulation that suppresses the inflammatory osteoclast-driven resorption that accelerates collapse. No single drug or surgical procedure addresses all three.

Clinical Evidence for MSC Therapy in AVN

The evidence base for MSC therapy in early-stage AVN has grown substantially over the past decade, with multiple randomised controlled trials and systematic reviews now available.

Core decompression with versus without MSCs. The most studied protocol combines core decompression — drilling a channel into the necrotic lesion to reduce intraosseous pressure — with implantation of autologous bone marrow concentrate (BMAC) or culture-expanded MSCs. A 2021 meta-analysis of 10 studies involving 632 hips found that core decompression with MSC augmentation reduced the rate of femoral head collapse by 48% and the rate of conversion to total hip arthroplasty by 52% compared to core decompression alone, at a mean follow-up of 48 months. [9]

Staging matters enormously. Subgroup analysis from the same meta-analysis showed that the benefit of MSC augmentation was concentrated in pre-collapse stages (I and II). At Stage III, the difference between the MSC and control groups narrowed, and at Stage IV the benefit was negligible. This reinforces the central clinical message: early intervention with MSCs before the femoral head collapses is where the evidence is strongest. [10]

Cell source and dose. Most trials used autologous bone marrow concentrate harvested from the iliac crest, with reported nucleated cell counts ranging from 1.5 × 10⁸ to 4.2 × 10⁸ cells per implantation. A smaller number of studies used culture-expanded allogeneic MSCs derived from umbilical cord tissue (Wharton's jelly), which offer the advantages of off-the-shelf availability, higher cell counts, and freedom from the morbidity of bone marrow harvest. Comparative data on autologous versus allogeneic sources in AVN are limited, though both approaches have demonstrated safety and efficacy signals in their respective trials. [11]

Hip survivorship at 5–10 years. A long-term follow-up study of 190 hips (Stage I–II AVN) treated with core decompression and BMAC reported 86% hip survivorship — defined as no progression to total hip arthroplasty — at 5 years and 71% at 10 years. Historical data for core decompression alone typically shows 50–60% survivorship at 5 years. The difference is clinically meaningful, particularly for patients in their 30s and 40s who wish to delay arthroplasty. [12]

The Treatment Procedure at VELAR Center

Treatment at VELAR Center follows a structured protocol designed to maximise the delivery of viable MSCs into the necrotic lesion while minimising procedural risk.

Step 1: Comprehensive Assessment

Every patient undergoes MRI of the affected joint to stage the AVN and assess lesion size, location, and the presence or absence of subchondral fracture. Blood work includes a coagulation panel, lipid profile, and inflammatory markers. Patients with identifiable risk factors — ongoing corticosteroid use, heavy alcohol consumption — receive counselling on risk-factor modification before treatment, since continued exposure undermines the regenerative effort.

Step 2: MSC Source Selection

VELAR Center offers two MSC sources: autologous bone marrow concentrate harvested from the iliac crest, and allogeneic Wharton's jelly-derived MSCs from our GMP-compliant cell partner. The choice is individualised: younger patients with healthy marrow may benefit from autologous cells; patients with compromised marrow function, bilateral disease, or preference for a single-procedure approach may opt for allogeneic cells. Both sources meet ISCT identity criteria (≥95% CD73⁺, CD90⁺, CD105⁺; ≤2% CD45⁻, CD34⁻).

Step 3: MSC Delivery

Under image guidance (fluoroscopy or CT), a cannula is advanced into the centre of the necrotic lesion. The MSC preparation is injected slowly under controlled pressure. For femoral head lesions, the procedure is typically performed as an outpatient day case under local anaesthesia with sedation. The entire delivery takes 30–45 minutes per joint.

Step 4: Post-Procedure Protocol

Patients are advised to use crutches with partial weight-bearing for 4–6 weeks to protect the treated joint during the early remodelling phase. A structured physiotherapy programme begins at week 2, focusing on maintaining range of motion and preventing muscle atrophy. Follow-up MRI at 3, 6, and 12 months tracks lesion healing — decreased marrow oedema, resolution of the necrotic zone, and new bone formation are the radiographic markers of a successful response.

Benefits and Limitations

What MSC Therapy Can Realistically Offer
  • Reduced intraosseous pressure and pain relief, often within 4–8 weeks
  • Arrest or significant slowing of lesion progression in Stage I–II disease
  • Avoidance or substantial delay of total hip arthroplasty in a majority of early-stage patients
  • Native joint preservation, which is particularly valuable for patients under 50
  • No implant-related complications, no risk of prosthetic infection or dislocation

Important Limitations to Understand
  • MSC therapy is still considered investigational for AVN; results vary between patients
  • Stage III–IV disease with femoral head collapse responds poorly — joint replacement remains the standard of care
  • Large lesions (>30% of femoral head volume) have a higher failure rate, even in early stages
  • Continued exposure to risk factors (corticosteroids, alcohol) significantly reduces treatment success
  • Long-term data beyond 10 years remains limited; the durability of MSC-regenerated bone requires further study
  • Not all patients are candidates — a thorough MRI-based assessment is essential before proceeding

Cost of MSC Therapy for Avascular Necrosis in Thailand

Treatment costs at VELAR Center depend on the MSC source chosen, the number of joints treated, and whether the procedure is combined with core decompression. As a guide, single-joint MSC therapy for AVN ranges from approximately USD 8,500 to 14,000. This compares to USD 4,000–8,000 for core decompression alone (which has a substantially higher failure rate) and USD 30,000–45,000 for total hip arthroplasty in the United States. Thailand's position as a medical tourism hub means that the total treatment cost, including travel and accommodation, is typically 40–60% lower than equivalent care in North America or Western Europe.

Frequently Asked Questions

How does MSC therapy compare to core decompression alone for AVN?

Core decompression reduces intraosseous pressure and may temporarily relieve pain, but it does not address the underlying biological deficit — dead bone and absent vasculature. Adding MSCs to core decompression provides the cellular machinery for angiogenesis and osteogenesis. Meta-analysis data shows a roughly 50% reduction in the rate of conversion to total hip arthroplasty when MSCs are added to core decompression for Stage I–II AVN.

What is the success rate of stem cell therapy for avascular necrosis?

Success depends heavily on disease stage. In Stage I–II AVN, studies report hip survivorship (no progression to joint replacement) of 80–90% at 5 years. In Stage III, this drops to approximately 50–60%. Stage IV AVN with established collapse shows minimal benefit from MSC therapy alone. Early diagnosis and treatment are the strongest predictors of a successful outcome.

Can AVN heal without surgery?

Spontaneous resolution of AVN is rare and limited to very small, early-stage lesions in patients who eliminate the underlying risk factor (e.g., discontinuing corticosteroids). For most patients, some form of intervention — core decompression, MSC therapy, bone grafting, or ultimately joint replacement — is required. MSC therapy occupies a middle ground: more biologically active than core decompression alone, less invasive and less irreversible than arthroplasty.

How many stem cell treatments are needed for AVN?

Most protocols involve a single treatment session. The MSCs are delivered once, after which they engraft, differentiate, and exert their paracrine effects over a period of weeks to months. Some patients with bilateral disease receive treatment to both hips in a single session. Repeat treatment is occasionally considered if follow-up MRI at 6–12 months shows incomplete healing, though this is uncommon when the initial treatment is delivered at the appropriate stage.

Is MSC therapy for AVN covered by insurance?

MSC therapy for AVN is generally classified as an investigational or experimental treatment and is not covered by most international insurance plans. Some Thai and Southeast Asian insurers offer limited coverage for regenerative procedures. Patients should check with their provider directly. VELAR Center provides detailed invoices and medical reports to support reimbursement claims where applicable.

What is recovery like after MSC therapy for AVN?

Recovery is typically faster and less painful than after joint replacement surgery. Most patients return to desk-based work within 1–2 weeks. Crutches with partial weight-bearing are recommended for 4–6 weeks. Physiotherapy begins at week 2. Full return to impact activities (running, jumping) typically requires 4–6 months and is guided by MRI evidence of bone healing. The absence of a surgical incision and prosthetic implant means there is no risk of wound infection, dislocation, or implant loosening.

Medical Disclaimer
MSC therapy for avascular necrosis is an investigational treatment. Results vary between patients and are strongly influenced by disease stage, lesion size, and risk-factor control. This article is for educational purposes only and does not constitute medical advice. Always consult a qualified orthopaedic specialist to determine the most appropriate treatment for your individual circumstances.

References

  1. Moya-Angeler J, Gianakos AL, Villa JC, Ni A, Lane JM. Current concepts on osteonecrosis of the femoral head. World Journal of Orthopedics. 2015;6(8):590-601. doi:10.5312/wjo.v6.i8.590 ↩
  2. Mont MA, Cherian JJ, Sierra RJ, Jones LC, Lieberman JR. Nontraumatic osteonecrosis of the femoral head: where do we stand today? A ten-year update. Journal of Bone and Joint Surgery. 2015;97(19):1604-1627. doi:10.2106/JBJS.O.00071 ↩
  3. Zalavras CG, Lieberman JR. Osteonecrosis of the femoral head: evaluation and treatment. Journal of the American Academy of Orthopaedic Surgeons. 2014;22(7):455-464. doi:10.5435/JAAOS-22-07-455 ↩
  4. Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clinical Orthopaedics and Related Research. 2002;(405):14-23. doi:10.1097/00003086-200212000-00003 ↩
  5. Steinberg ME, Hayken GD, Steinberg DR. A quantitative system for staging avascular necrosis. Journal of Bone and Joint Surgery (British). 1995;77-B(1):34-41. doi:10.1302/0301-620X.77B1.7822393 ↩
  6. Fan L, Zhang C, Yu Z, et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells for the treatment of steroid-induced osteonecrosis of the femoral head. Stem Cell Research & Therapy. 2019;10(1):250. doi:10.1186/s13287-019-1347-1 ↩
  7. Gao Y, Zhu Z, Shi Z, et al. Bone marrow mesenchymal stem cells combined with core decompression for the treatment of osteonecrosis of the femoral head: a meta-analysis. Journal of Orthopaedic Surgery and Research. 2020;15(1):373. doi:10.1186/s13018-01903-5 ↩
  8. Wang C, Meng H, Wang X, Zhao C, Peng J, Wang Y. Differentiation of bone marrow mesenchymal stem cells in osteoblasts and adipocytes and its role in treatment of osteoporosis. Medical Science Monitor. 2016;22:226-233. doi:10.12659/MSM.897044 ↩
  9. Wang Z, Sun QM, Zhang FQ, et al. Core decompression combined with autologous bone marrow stem cells versus core decompression alone for osteonecrosis of the femoral head: a systematic review and meta-analysis. International Journal of Surgery. 2021;93:106038. doi:10.1016/j.ijsu.2021.106038 ↩
  10. Kang JS, Moon KH, Kim BS, et al. Clinical results of core decompression with bone marrow aspirate concentrate for osteonecrosis of the femoral head. Hip & Pelvis. 2017;29(2):104-112. doi:10.5371/hp.2017.29.2.104 ↩
  11. Chen C, Qu Z, Yin X, et al. Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy on osteonecrosis of the femoral head: a systematic review and meta-analysis. Stem Cells International. 2022;2022:6795273. doi:10.1155/2022/6795273 ↩
  12. Hernigou P, Poignard A, Zilber S, Rouard H. Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian Journal of Orthopaedics. 2009;43(1):40-45. doi:10.4103/0019-5413.45322 ↩
  13. Zhao D, Cui D, Wang B, et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone. 2012;50(1):325-330. doi:10.1016/j.bone.2011.11.002 ↩
  14. Hauzeur JP, De Maertelaer V, Baudoux E, Malaise M, Beguin Y, Gangji V. Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a randomized controlled double-blind trial. International Orthopaedics. 2018;42(7):1429-1435. doi:10.1007/s00264-017-3650-8 ↩
  15. Pittenger MF, Discher DE, Peault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩